- Home
- TECX vs IMAB Comparison
TECX vs IMAB Comparison
Compare TECX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- IMAB
- Stock Information
- Founded
- TECX 2019
- IMAB 2014
- Country
- TECX United States
- IMAB United States
- Employees
- TECX N/A
- IMAB N/A
- Industry
- TECX
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- IMAB Health Care
- Exchange
- TECX Nasdaq
- IMAB Nasdaq
- Market Cap
- TECX 387.1M
- IMAB 394.2M
- IPO Year
- TECX 2018
- IMAB 2020
- Fundamental
- Price
- TECX $15.34
- IMAB $5.21
- Analyst Decision
- TECX Buy
- IMAB Strong Buy
- Analyst Count
- TECX 6
- IMAB 6
- Target Price
- TECX $79.17
- IMAB $7.17
- AVG Volume (30 Days)
- TECX 480.8K
- IMAB 1.6M
- Earning Date
- TECX 11-06-2025
- IMAB 11-02-2025
- Dividend Yield
- TECX N/A
- IMAB N/A
- EPS Growth
- TECX N/A
- IMAB N/A
- EPS
- TECX N/A
- IMAB N/A
- Revenue
- TECX N/A
- IMAB N/A
- Revenue This Year
- TECX N/A
- IMAB N/A
- Revenue Next Year
- TECX N/A
- IMAB N/A
- P/E Ratio
- TECX N/A
- IMAB N/A
- Revenue Growth
- TECX N/A
- IMAB N/A
- 52 Week Low
- TECX $13.70
- IMAB $0.60
- 52 Week High
- TECX $61.07
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- TECX 36.96
- IMAB 66.44
- Support Level
- TECX $14.62
- IMAB $3.98
- Resistance Level
- TECX $15.47
- IMAB $4.51
- Average True Range (ATR)
- TECX 0.91
- IMAB 0.31
- MACD
- TECX 0.20
- IMAB 0.11
- Stochastic Oscillator
- TECX 23.04
- IMAB 100.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).